EGFR and non-small cell lung carcinoma: This case represents one of the longest reported durations of response to Olaparib in an EGFR and BRCA2 co-mutated NSCLC patient with leptomeningeal metastases, underscoring the potential of PARP inhibitors in combination with targeted therapy and intrathecal chemotherapy for managing this challenging patient population.